AMRX
Income statement / Annual
Last year (2024), Amneal Pharmaceuticals, Inc.'s total revenue was $2.79 B,
an increase of 16.73% from the previous year.
In 2024, Amneal Pharmaceuticals, Inc.'s net income was -$116.89 M.
See Amneal Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$2.79 B |
$2.39 B |
$2.21 B |
$2.09 B |
$1.99 B |
$1.63 B |
$1.66 B |
$1.03 B |
$1.02 B |
$866.28 M |
| Cost of Revenue |
$1.77 B
|
$1.57 B
|
$1.43 B
|
$1.32 B
|
$1.36 B
|
$1.27 B
|
$946.59 M
|
$507.48 M
|
$420.77 M
|
$367.05 M
|
| Gross Profit |
$1.02 B
|
$820.57 M
|
$784.71 M
|
$768.97 M
|
$628.39 M
|
$353.00 M
|
$716.40 M
|
$526.18 M
|
$597.46 M
|
$499.23 M
|
| Gross Profit Ratio |
0.37
|
0.34
|
0.35
|
0.37
|
0.32
|
0.22
|
0.43
|
0.51
|
0.59
|
0.58
|
| Research and Development Expenses |
$196.56 M
|
$167.78 M
|
$200.05 M
|
$209.56 M
|
$190.59 M
|
$202.29 M
|
$210.45 M
|
$191.94 M
|
$204.75 M
|
$136.87 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$230.44 M
|
$109.05 M
|
$118.76 M
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$476.44 M
|
$429.68 M
|
$399.70 M
|
$365.50 M
|
$326.73 M
|
$289.60 M
|
$230.44 M
|
$109.05 M
|
$118.76 M
|
$109.68 M
|
| Other Expenses |
$98.12 M
|
$18.74 M
|
-$3.96 M
|
$15.33 M
|
$2.59 M
|
$1.47 M
|
$2.85 M
|
-$47,000.00
|
-$669,000.00
|
$0.00
|
| Operating Expenses |
$771.11 M
|
$616.19 M
|
$595.79 M
|
$575.07 M
|
$517.31 M
|
$491.89 M
|
$440.89 M
|
$300.98 M
|
$323.50 M
|
$277.81 M
|
| Cost And Expenses |
$2.54 B
|
$2.19 B
|
$2.02 B
|
$1.90 B
|
$1.88 B
|
$1.77 B
|
$1.39 B
|
$808.46 M
|
$744.27 M
|
$644.86 M
|
| Interest Income |
$0.00
|
$0.00
|
$158.38 M
|
$136.33 M
|
$146.00 M
|
$168.21 M
|
$0.00
|
$0.00
|
$0.00
|
$45.84 M
|
| Interest Expense |
$258.60 M
|
$210.63 M
|
$158.38 M
|
$136.33 M
|
$146.00 M
|
$168.21 M
|
$143.57 M
|
$71.06 M
|
$55.28 M
|
$0.00
|
| Depreciation & Amortization |
$236.19 M
|
$229.40 M
|
$240.18 M
|
$233.41 M
|
$235.39 M
|
$207.24 M
|
$137.40 M
|
$45.94 M
|
$33.02 M
|
$25.45 M
|
| EBITDA |
$439.77 M |
$399.76 M |
$150.43 M |
$450.00 M |
$381.05 M |
$155.20 M |
-$19.67 M |
$271.13 M |
$306.97 M |
$252.68 M |
| EBITDA Ratio |
0.16
|
0.17
|
0.2
|
0.21
|
0.18
|
0.04
|
0.25
|
0.26
|
0.3
|
0.29
|
| Operating Income Ratio |
0.09
|
0.09
|
0.09
|
0.1
|
0.05
|
-0.08
|
-0.01
|
0.24
|
0.28
|
0.26
|
| Total Other Income/Expenses Net |
-$304.34 M
|
-$244.64 M
|
-$153.20 M
|
-$121.35 M
|
-$126.94 M
|
$28.44 M
|
-$183.05 M
|
-$73.78 M
|
-$70.06 M
|
-$60.58 M
|
| Income Before Tax |
-$55.01 M
|
-$40.27 M
|
-$248.13 M
|
$31.37 M
|
-$35.78 M
|
-$220.24 M
|
-$202.72 M
|
$171.32 M
|
$214.82 M
|
$175.58 M
|
| Income Before Tax Ratio |
-0.02
|
-0.02
|
-0.11
|
0.01
|
-0.02
|
-0.14
|
-0.12
|
0.17
|
0.21
|
0.2
|
| Income Tax Expense |
$18.86 M
|
$8.45 M
|
$6.66 M
|
$11.20 M
|
-$104.36 M
|
$383.33 M
|
-$1.42 M
|
$2.00 M
|
$5.40 M
|
$4.95 M
|
| Net Income |
-$116.89 M
|
-$83.99 M
|
-$254.79 M
|
$20.17 M
|
$68.58 M
|
-$603.57 M
|
-$169.73 M
|
$167.65 M
|
$207.38 M
|
$169.45 M
|
| Net Income Ratio |
-0.04
|
-0.04
|
-0.12
|
0.01
|
0.03
|
-0.37
|
-0.1
|
0.16
|
0.2
|
0.2
|
| EPS |
-0.38 |
-0.48 |
-1.69 |
0.14 |
0.47 |
-4.57 |
-1.33 |
1.46 |
1.81 |
0.9 |
| EPS Diluted |
-0.38 |
-0.48 |
-1.69 |
0.13 |
0.46 |
-4.57 |
-1.33 |
1.46 |
1.81 |
0.9 |
| Weighted Average Shares Out |
$308.98 M
|
$174.99 M
|
$150.94 M
|
$148.92 M
|
$147.44 M
|
$132.09 M
|
$127.25 M
|
$114.86 M
|
$114.86 M
|
$189.00 M
|
| Weighted Average Shares Out Diluted |
$308.98 M
|
$176.14 M
|
$150.94 M
|
$151.82 M
|
$148.91 M
|
$132.11 M
|
$127.25 M
|
$114.86 M
|
$114.86 M
|
$189.00 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
